Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence

被引:30
作者
He, R
Liu, B
Yang, C
Yang, RC
Tobelem, G
Han, ZC [1 ]
机构
[1] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Hosp Blood Dis, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Hop Lariboisiere, Inst Vaisseaux & Sang, F-75475 Paris, France
基金
中国国家自然科学基金;
关键词
antisense-VEGF; leukemia; angiogenesis; gene therapy; ACUTE MYELOID-LEUKEMIA; TUMOR ANGIOGENESIS; FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; CANCER; CELLS; MALIGNANCIES; PARACRINE; HEMATOPOIESIS; METASTASIS;
D O I
10.1038/sj.cgt.7700645
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Vascular endothelial growth factor (VEGF), a major angiogenic factor, plays a key role in the growth of solid tumor. Recently, expression of VEGF and its receptors has been found on leukemic cells as well as on endothelial cells. VEGF may fulfill a fundamental role in promoting tumor angiogenesis and proliferation by stimulating both endothelial cells and leukemic cells. To investigate the role of VEGF in the angiogenesis and growth of leukemic cell, we used an antisense strategy to downregulate VEGF expression in K562 cells, a human erythroleukemia cell line. Expression of antisense-VEGF in K562 cells reduced the secretion of VEGF protein and inhibited cell survival. The proliferation and migration of human umbilical vein endothelial cells were decreased in response to the conditioned medium (CM) from K562 cells expressed antisense-VEGF, compared to CM from K562 cells transfected with vector control. Moreover, subcutaneous injection of nude mice with antisense-VEGF K562 cells inhibited tumor growth with a reduction of the density of microvessels and an increased apoptosis in those tumors, compared to vector control K562 cells. These results suggest that the efficient downregulation of the VEGF production in leukemic cells using antisense-VEGF may constitute a novel strategy of treatment in leukemia.
引用
收藏
页码:879 / 886
页数:8
相关论文
共 32 条
[1]   Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].
Aguayo, A ;
Kantarjian, H ;
Manshouri, T ;
Gidel, C ;
Estey, E ;
Thomas, D ;
Koller, C ;
Estrov, Z ;
O'Brien, S ;
Keating, M ;
Freireich, E ;
Albitar, M .
BLOOD, 2000, 96 (06) :2240-2245
[2]  
Aguayo A, 2000, BLOOD, V96, P768
[3]   Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [J].
Aguayo, A ;
Estey, E ;
Kantarjian, H ;
Mansouri, T ;
Gidel, C ;
Keating, M ;
Giles, F ;
Estrov, Z ;
Barlogie, B ;
Albitar, M .
BLOOD, 1999, 94 (11) :3717-3721
[4]  
Bellamy WT, 1999, CANCER RES, V59, P728
[5]   Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression [J].
Brogi, E ;
Schatteman, G ;
Wu, T ;
Kim, EA ;
Varticovski, L ;
Keyt, B ;
Isner, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (02) :469-476
[6]   Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias [J].
Dias, S ;
Hattori, K ;
Heissig, B ;
Zhu, ZP ;
Wu, Y ;
Witte, L ;
Hicklin, DJ ;
Tateno, M ;
Bohlen, P ;
Moore, MAS ;
Rafii, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10857-10862
[7]   Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration [J].
Dias, S ;
Hattori, K ;
Zhu, ZP ;
Heissig, B ;
Choy, M ;
Lane, W ;
Wu, Y ;
Chadburn, A ;
Hyjek, E ;
Gill, M ;
Hicklin, DJ ;
Witte, L ;
Moore, MAS ;
Rafii, S .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) :511-521
[8]   VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition [J].
Dias, S ;
Shmelkov, SV ;
Lam, G ;
Rafii, S .
BLOOD, 2002, 99 (07) :2532-2540
[9]   VEGF and vascular fusion: Implications for normal and pathological vessels [J].
Drake, CJ ;
Little, CD .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1999, 47 (11) :1351-1355
[10]   Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia [J].
Fiedler, W ;
Graeven, U ;
Ergun, S ;
Verago, S ;
Kilic, N ;
Stockschlader, M ;
Hossfeld, DK .
BLOOD, 1997, 89 (06) :1870-1875